Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TG-4010 Transgene.

Seth Cohen1, Howard L Kaufman

  • 1Department of Surgery, Columbia University, 177 Fort Washington Avenue, New York, NY 10032, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|January 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and clinical features of cataracts: an under-recognized adverse event with mirvetuximab soravtansine-gynx in ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Local immunotherapy for the treatment of cancer: scientific advances and clinical potential.

Journal for immunotherapy of cancer·2026
Same author

Fusariosis in Patients With Hematologic Malignancies in the Era of Antifungal Prophylaxis.

Transplant infectious disease : an official journal of the Transplantation Society·2026
Same author

Temporal molecular remodeling of T cells informs their possible adaptation in 4T1 tumors.

Computational and structural biotechnology journal·2026
Same author

Targeting Tumor-Draining Lymph Nodes to Improve the Therapeutic Potential of Oncolytic Viruses.

Cancer immunology research·2026
Same author

Locally Advanced Conjunctival Squamous Cell Carcinoma not Responsive to Immune Checkpoint Inhibitor Therapy: 3 Cases and a Literature Review.

Ophthalmic plastic and reconstructive surgery·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Transgene is developing TG-4010, a novel cancer immunotherapy. This modified vaccinia Ankara virus shows potential for treating non-small-cell lung, renal, and prostate cancers in ongoing Phase II trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Virology

Background:

  • Cancer immunotherapy aims to harness the immune system to fight tumors.
  • Modified vaccinia Ankara virus is a promising viral vector for vaccine development.
  • MUC1 and interleukin-2 are key targets and modulators in cancer immunity.

Purpose of the Study:

  • To evaluate TG-4010, a novel cancer immunotherapy.
  • To assess the potential of TG-4010 in treating various cancer types.
  • To advance TG-4010 through Phase II clinical trials.

Main Methods:

  • Development of TG-4010, a second-generation modified vaccinia virus Ankara.
  • Engineering the virus to encode MUC1 tumor antigen and interleukin-2.
  • Conducting Phase II clinical trials for specific cancer indications.

Related Experiment Videos

Main Results:

  • TG-4010 is under investigation as a potential cancer therapeutic.
  • Ongoing trials are evaluating its efficacy in non-small-cell lung cancer, metastatic renal cancer, and prostate cancer.
  • The study focuses on a novel approach combining viral vector technology with specific tumor antigens and immune stimulants.

Conclusions:

  • TG-4010 represents a novel immunotherapy candidate for diverse cancers.
  • Phase II trials are crucial for determining the clinical utility of TG-4010.
  • Further research will elucidate the full therapeutic potential of this oncolytic virus therapy.